Black Rock Inc. Nurix Therapeutics, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NRIX
# of Institutions
185Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Vanguard Group Inc Valley Forge, PA4.35MShares$44.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$42.9 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$39.8 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$30.8 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$30.7 Million2.49% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $483M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...